10 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 17 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 10, Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 4, Recruiting 1, Terminated 1, Unknown 1 |
Follow Hemangiosarcoma: new trials by email Literature Review of Hemangiosarcoma trials Research Report on Hemangiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors AGX101 - Cancer, Advanced Cancer | Phase 1 | Recruiting | Angiex, Inc. | 80 | 2024-07-22 | 2026-09-09 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Botensilimab, Balstilimab - Advanced Cancer, Angiosarcoma | Phase 1 | Active not recruiting | Agenus Inc. | 499 | 2019-03-20 | 2026-03-30 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) PROPRANOLOL - Angiosarcoma | Phase 1 / Phase 2 | Unknown | Assistance Publique Hopitaux De Marseille | 24 | 2016-05-01 | 2016-04-11 |
| A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma TRC105 and Pazopanib - Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 111 | 2013-12-10 | 2020-05-20 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2016-05-17 |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma oral belinostat - Solid Tumor, Lymphoma | Phase 1 | Completed | Valerio Therapeutics | 121 | 2006-06-01 | 2015-07-08 |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors belinostat, 5-Fluorouracil (5-FU) - Tumor | Phase 1 | Completed | Valerio Therapeutics | 35 | 2005-09-01 | 2015-07-08 |
| Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery celecoxib, adjuvant therapy, radiation therapy - Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma | Phase 1 | Completed | University of Miami | 3 | 2004-03-01 | 2016-12-15 |
| Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma ifosfamide, pegylated liposomal doxorubicin hydrochloride - Sarcoma | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 28 | 2001-11-01 | 2012-09-24 |
| STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma imatinib mesylate - Endometrial Cancer, Gastrointestinal Stromal Tumor | Phase 1 / Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 91 | 2000-08-01 | 2012-09-24 |
Sarcoma (11) · Fibrosarcoma (9) · Leiomyosarcoma (9) · Liposarcoma (9) · Histiocytoma, Malignant Fibrous (8) · Sarcoma, Synovial (8) · Neurofibrosarcoma (7) · Chondrosarcoma (5) · Osteosarcoma (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Dermatofibrosarcoma (4) · Hemangiopericytoma, Malignant (4) · Malignant mesenchymal tumor (4) · Ovarian Neoplasms (4)
Neoplasms by Histologic Type (17) · Neoplasms, Connective and Soft Tissue (17) · Neoplasms, Vascular Tissue (17) · Neoplasms (14) · Neoplasms, Connective Tissue (10) · Neoplasms, Fibrous Tissue (10) · Neoplasms, Muscle Tissue (9) · Histiocytoma (8) · Neoplasms by Site (8) · Neoplasms, Adipose Tissue (8) · Neoplasms, Nerve Tissue (8) · Urogenital Diseases (8) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7)
Doxorubicin (4) · Ifosfamide (3) · belinostat (2) · pazopanib (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Celecoxib (1) · Chemotherapy, Adjuvant (1) · Cisplatin (1) · Dacarbazine (1) · Epirubicin (1) · Filgrastim (1) · Fluorouracil (1) · Granulocyte Colony-Stimulating Factor (1) · HhAntag691 (1) · Imatinib Mesylate (1)
European Organisation for Research and Treatment of Cancer - EORTC (2) · National Cancer Institute (NCI) (2) · Valerio Therapeutics (2) · Agenus Inc. (1) · Angiex, Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Grupo Espanol de Investigacion en Sarcomas (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · OHSU Knight Cancer Institute (1) · St. Jude Children's Research Hospital (1) · Tracon Pharmaceuticals Inc. (1) · University of Miami (1) · iOmx Therapeutics AG (1)
United States (11) · United Kingdom (4) · Denmark (3) · France (3) · Belgium (2) · Spain (2) · Germany (1) · Italy (1) · Netherlands (1)
Aaron H. Wolfson, MD (1) · Alba Rubio (1) · Antonio Casado (1) · Charles Theuer, MD (1) · Claudia Valverde (1) · Cristina Mata (1) · Emanuela Palmerini (1) · Giovanni Grignani (1) · Glen Weiss, MD (1) · Irene Carrasco (1) · Jacob Verweij, MD, PhD (1)
PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15592836, PMID 19088049, PMID 25858498, PMID 31401903, PMID 33203665, PMID 38871975, PMID 39356980, PMID 39869830, PMID 41502912, PMID 41836677
2015 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA014599 (1), U01CA069856 (1)